Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after ...

Pfizer shares were rising early Tuesday after the company reported fourth-quarter earnings and revenue that came in ahead of ...

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...

The CEO said he remained “cautiously optimistic ... As well as, falling in tandem with the release of Pfizer’s annual earnings report, which reflected revenues of $63.6 billion.

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

Pfizer CEO Albert Bourla revealed to stakeholders this week that the rendezvous took place in December, a few weeks after RFK Jr was nominated to head the Department of Health and Human Services ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

Pfizer's CEO Albert Bourla said that he's had dinner with Trump's health secretary pick, RFK Jr. Bourla said he was "cautiously optimistic" about the new administration. Kennedy is now close to ...